Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
motivated scientist with: A PhD or MD Knowledge of Biochemistry/Molecular Biology Experience with stem cell models (required) Experience in brain analysis (desirable) About us and what we offer Located within
-
total. The starting date is as agreed, typically between August and December 2025. The position includes a six-month trial period. The research action Systems of Food and Drug Security (fooDrug) brings
-
PhD Thesis based on ABIS. The main areas have so far been studies on the development of Type 1 diabetes, but also studies on celiac disease, JIA, IBD, autism, obesity, allergy and recently also
-
genetics to join the Pioneer Centre for SMARTbiomed at the Center for Quantitative Genetics and Genomics (QGG), Aarhus University. The position is for 2.5 years, starting on September 1, 2025, or as soon as
-
PhD graduate in immunology, molecular biology, cell biology, biochemistry, or related fields Strong expertise in innate immunity, cancer immunology, or molecular biology Prior experience with immunology
-
List of Publications please visit here . Your qualifications should include: · PhD or M.D. Expertise in using mouse models to study metabolic diseases is preferred. · Extensive experience
-
: · PhD or M.D. with a strong background and profound knowledge in the field of either molecular biology, immunology, cancer biology, experience in sequencing or protein structural data analysis is highly
-
has a PhD and experience in the field of cell and gene therapy for cancer and who has recent experience of primary T cell culture, CARTs, immune assays, flow cytometry, molecular cloning, retroviral
-
or spatial transcriptomic data analysis Candidates who are nearing completion of their PhD may apply, but confirmation on awarded PhD is required within 6 months of employment. The ICR has a workforce
-
of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). We are seeking scientists to lead research projects with a specific focus on the genetic determinants of severe adverse drug and vaccine reactions